Pieris Pharmaceuticals: Q3 Earnings Snapshot
Pieris Pharmaceuticals Inc. (PIRS) on Wednesday reported a loss of $2.9 million in its third quarter. On a per-share basis, the Boston-based company said it had a loss of $2.19. This story was generated by Automated Insights ( using data from Zacks Investment Research.
Ars Pharmaceuticals, Inc. ( (SPRY)) has released its Q3 earnings. Here is a breakdown of the information Ars Pharmaceuticals, Inc. presented to its investors. ARS Pharmaceuticals, Inc., a ...
ARS Pharmaceuticals, Inc. (SPRY) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.16 per share a year ago.
Investor's Business Daily on MSN3d
ARS Pharma Jumps After Inking $145 Million Deal For Epinephrine Nasal SprayARS Pharmaceuticals shares jumped Monday after the company inked a deal to commercialize its allergic reaction nasal spray internationally.
Cantor Fitzgerald has recently initiated ARS Pharmaceuticals Inc (SPRY) stock to Overweight rating, as announced on August 20, 2024, according to Finviz. Earlier, on August 13, 2024, Raymond James had ...
On Saturday, Denmark-based ALK entered into a strategic license agreement with ARS Pharmaceuticals, Inc. (NASDAQ:SPRY). The agreement grants ALK exclusive global rights to the neffy adrenaline ...
Plus: How AI can make it easier to find drugs from nature and a study suggests Ozempic could treat alcoholism.
In a report released on November 11, Roanna Ruiz from Leerink Partners maintained a Buy rating on ARS Pharmaceuticals (SPRY – Research Report). The company’s shares closed yesterday at $16.61.
Although ARS Pharmaceuticals’ approval for its epinephrine nasal spray came later than expected, the company ultimately received a thumbs up from the FDA in August and is now moving fast to expand ...
ARS Pharmaceuticals has a fifty-two week low of $3.38 and a fifty-two week high of $17.08. ARS Pharmaceuticals (NASDAQ:SPRY – Get Free Report) last posted its earnings results on Tuesday, ...
ARS Pharmaceuticals (SPRY) announced a licensing agreement with ALK-Abello A/S (AKBLF), that provides ALK exclusive rights to commercialize ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback